Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Phase 4 Completed 266 enrolled Allergan

RandomizedParallel-groupSingle-blindTreatment

Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Timeline

Start: 2006-08
Primary completion: 2007-10
Completion: 2007-10

Publications

Background Kammer JA, Katzman B, Ackerman SL, Hollander DA. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Br J Ophthalmol. 2010 Jan;94(1):74-9. doi: 10.1136/bjo.2009.158071. Epub 2009 Sep 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimatoprost	Other / unclassified	0.03 %	Other
Comparator	Travoprost	Other / unclassified	0.004 %	Other

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Summary

Timeline

Publications

Drugs

Indications